Page last updated: 2024-11-05

funiculosin (anthraquinone)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

funiculosin (anthraquinone): see also a pyridone cpd called funiculosin; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10151
CHEMBL ID477724
CHEBI ID80733
SCHEMBL ID9172900
MeSH IDM0064434

Synonyms (36)

Synonym
einecs 207-506-2
brn 2059061
1,4,5-trihydroxy-2-methyl-9,10-anthracenedione
anthraquinone, 1,4,5-trihydroxy-2-methyl-
9,10-anthracenedione, 1,4,5-trihydroxy-2-methyl-
1,4,5-trihydroxy-2-methylanthraquinone
ccris 3476
funiculosin (van)
nsc 264955
rhodomycin
funiculosin (anthraquinone)
NCI60_002123
9, 1,4,5-trihydroxy-2-methyl-
islandin
nsc-264955
islandicin
funiculosin
nsc264955 ,
476-56-2
rhodomycelin
anthraquinone,4,5-trihydroxy-2-methyl-
1,4,5-trihydroxy-2-methyl-anthracene-9,10-dione
1,4,5-trihydroxy-2-methylanthra-9,10-quinone
1,4,5-trihydroxy-2-methylanthracene-9,10-dione
CHEMBL477724
chebi:80733 ,
unii-vvj2ulr2m5
vvj2ulr2m5 ,
4-08-00-03572 (beilstein handbook reference)
FT-0603404
SCHEMBL9172900
1,4,5-trihydroxy-2-methylanthra-9,10-quinone #
FHFHNVHRVKQQHN-UHFFFAOYSA-N
DTXSID70197214
Q27149783
1,4,5-trihydroxy-2-methyl-9,10-dihydroanthracene-9,10-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
trihydroxyanthraquinoneA member of the class of hydroxyanthraquinones carrying three hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID360633Inhibition of human K562 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID360640Inhibition of human Raji cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID360647Inhibition of african green monkey Vero cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID689849Cytotoxicity against human NCI-H2887 cells after 96 hrs by Cell Titer Glo assay2012Journal of natural products, Oct-26, Volume: 75, Issue:10
Anthraquinones from a marine-derived Streptomyces spinoverrucosus.
AID360618Inhibition of human Calu1 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID689848Cytotoxicity against human Calu3 cells after 96 hrs by Cell Titer Glo assay2012Journal of natural products, Oct-26, Volume: 75, Issue:10
Anthraquinones from a marine-derived Streptomyces spinoverrucosus.
AID360626Inhibition of human HeLa cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID360654Inhibition of human WISH cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (49.06)18.7374
1990's13 (24.53)18.2507
2000's9 (16.98)29.6817
2010's5 (9.43)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.16 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other55 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]